Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm Technologies (NASDAQ: IRTC) will announce its first-quarter 2022 financial results after trading closes on May 5, 2022. The management team will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. iRhythm specializes in cardiac care through its innovative wearable biosensor devices and cloud-based analytics, which aim to enhance arrhythmia detection and management. Interested investors can access the live and archived call via the company’s website.
iRhythm Technologies (NASDAQ: IRTC) presented promising clinical research at ACC.22, highlighting the effectiveness of its Zio service for early detection of silent atrial fibrillation (AF). Key findings include:
- Zio AT reduced hospital resources, saving a healthcare system 136 inpatient days.
- 4.5% of high-risk patients using Zio XT were diagnosed with AF within two weeks.
- Post-TAVR monitoring with Zio AT revealed a significant incidence of arrhythmias, notably AF in 25% of patients.
This data underscores Zio’s role in improving patient care and hospital workflows, particularly amidst ongoing healthcare challenges.
iRhythm Technologies announced an amended credit facility with Silicon Valley Bank, enhancing its borrowing capacity to $100 million. This includes a term loan of $75 million and a revolving credit line of $25 million, maturing on March 1, 2027. The company has drawn down $35 million to pay off previous debt and fund working capital. This non-dilutive financing strengthens iRhythm's financial position, supporting growth in cardiac care through advanced monitoring solutions.
iRhythm Technologies, Inc. (NASDAQ: IRTC) announced the retirement of Kevin King from its Board of Directors, effective April 1, 2022. King joined the Board in July 2012 and previously led the company as President and CEO until January 2021. His leadership was pivotal in iRhythm's growth and success in cardiac care, where it has served over four million patients. Quentin Blackford, current President and CEO, expressed gratitude for King's contributions, highlighting his role in establishing the company as a leader in cardiac monitoring technology.
iRhythm Technologies (NASDAQ: IRTC) announced positive findings from the KP-Rhythm2 study, confirming that its Zio XT cardiac monitoring patch effectively detects bradyarrhythmias in patients undergoing transcatheter aortic valve replacement (TAVR).
The study shows Zio XT significantly outperforms Holter and event monitors in diagnosing arrhythmias, leading to more timely interventions and reduced healthcare costs.
iRhythm Technologies reported its Q4 and full-year 2021 financial results, showing a 3.8% increase in revenue to $81.8 million for Q4, while full-year revenue rose 21.7% to $322.8 million. However, gross margins declined to 62.7% in Q4 and 66.2% for the year due to lower Zio XT reimbursement rates and rising costs. The company posted a Q4 net loss of $32.5 million and a full-year net loss of $101.4 million. For 2022, iRhythm projects revenue growth of 24% to 27% and expects adjusted EBITDA to remain negative, ranging from negative $30 to $40 million.
Galderma, the largest independent dermatology company, announced the appointment of Karen L. Ling to its Advisory Committee, effective March 1, 2022. Ms. Ling brings over 25 years of global human resources experience from executive positions at AIG, Allergan, Merck, and Wyeth, focusing on talent management and organizational culture. Currently, she serves on the Boards of iRhythm Technologies (NASDAQ: IRTC) and TherapeuticsMD (NASDAQ: TXMD). Both Thomas Ebeling and Flemming Ørnskov expressed enthusiasm about her joining, highlighting her strengths in human capital management and diversity initiatives.
iRhythm Technologies (NASDAQ: IRTC) announced its fourth-quarter and full-year 2021 financial results will be released on February 23, 2022, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. iRhythm specializes in cardiac care through digital health solutions, utilizing wearable biosensors and cloud-based analytics to revolutionize arrhythmia diagnosis. The company is set to highlight advancements in patient monitoring and clinical management.
On January 10, 2022, iRhythm Technologies (NASDAQ:IRTC) announced that Novitas Solutions updated the reimbursement rates for CPT codes 93243 and 93247, applicable to their Zio service, to $223 and $233, retroactive to January 1, 2022. This adjustment could have boosted 2021 revenues by approximately 10%, offering clarity as the company moves into 2022. CEO Quentin Blackford expressed gratitude towards Novitas and other stakeholders, emphasizing the continued efforts in advancing cardiac monitoring services. Full financial details for Q4 and FY 2021 will be shared in February.
iRhythm Technologies (NASDAQ: IRTC) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s website. iRhythm is a leader in digital healthcare, focusing on cardiac care through wearable biosensor devices and cloud-based analytics. Their innovations aim to enhance the detection and management of cardiac arrhythmias, potentially transforming patient care.
FAQ
What is the current stock price of iRhythm Holdings (IRTC)?
What is the market cap of iRhythm Holdings (IRTC)?
